CIK 0000744218 · Large accelerated filer
Celldex Therapeutics, Inc.
Sign in to watch- Ticker
- CLDX
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 133191702
- Phone
- 908-200-7500
- Business address
- 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827
- Former names
- AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-11 | Heath-Chiozzi Margo SVP of Regulatory Affairs | Option exercise · Incentive Stock Option | −10,000 | 8,332 | ||
| 2021-08-11 | Jimenez Freddy A. SVP & General Counsel | Purchase | +430 | $46.28 | $20K | 430 |
| 2021-08-10 | Martin Samuel Bates SVP and CFO | Option exercise | +10,302 | $9.02 | $93K | 21,037 |
| 2021-08-10 | Martin Samuel Bates SVP and CFO | Sale | −2,056 | $45.25 | $93K | 18,981 |
| 2021-08-10 | Martin Samuel Bates SVP and CFO | Option exercise | +11,079 | $2.78 | $31K | 30,060 |
| 2021-08-10 | Martin Samuel Bates SVP and CFO | Sale | −682 | $45.25 | $31K | 29,378 |
| 2021-08-10 | Martin Samuel Bates SVP and CFO | Option exercise · Incentive Stock Option | −10,302 | 16,030 | ||
| 2021-08-10 | Martin Samuel Bates SVP and CFO | Option exercise · Incentive Stock Option | −11,079 | 31,921 | ||
| 2021-08-05 | Marucci Anthony S President & CEO | Option exercise | +3,537 | $42.00 | $149K | 27,231 |
| 2021-08-05 | Marucci Anthony S President & CEO | Option exercise · Incentive Stock Option | −3,537 | 0 | ||
| 2021-06-17 | Jimenez Freddy A. SVP & General Counsel | Grant or award · Incentive Stock Option (right to buy) | +73,000 | 73,000 | ||
| 2021-06-17 | Young Diane C. SVP, Chief Medical Officer | Grant or award · Incentive Stock Option (right to buy) | +72,000 | 72,000 | ||
| 2021-06-17 | Heath-Chiozzi Margo SVP of Regulatory Affairs | Grant or award · Incentive Stock Option (right to buy) | +62,500 | 62,500 | ||
| 2021-06-17 | Wright Richard M. Sr. VP & CCO | Grant or award · Incentive Stock Option (right to buy) | +42,000 | 42,000 | ||
| 2021-06-17 | Cavanaugh Sarah SVP of Corp Affairs & Admin. | Grant or award · Incentive Stock Option (right to buy) | +56,000 | 56,000 | ||
| 2021-06-17 | PEPIN RONALD Sr. VP & CBO | Grant or award · Incentive Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2021-06-17 | Crowley Elizabeth Sr. VP &CPDO | Grant or award · Incentive Stock Option (right to buy) | +58,000 | 58,000 | ||
| 2021-06-17 | Martin Samuel Bates SVP and CFO | Grant or award · Incentive Stock Option (right to buy) | +85,000 | 85,000 | ||
| 2021-06-17 | KELER TIBOR Executive VP & CSO | Grant or award · Incentive Stock Option (right to buy) | +91,000 | 91,000 | ||
| 2021-06-17 | Marucci Anthony S President & CEO | Grant or award · Incentive Stock Option (right to buy) | +224,000 | 224,000 |
Page 13 of 17 · 325 trades